1/ 🏥 Let’s talk #OvarianCancer treatment strategies. Our SUROVA project took a closer look at a key debate: PDS vs NACT + interval debulking. Why do survival curves “cross” at 24 months—NACT looking better early on, but PDS edging ahead later? Let’s unpack it!

#LeadArticle #SUROVAstudy: global real-world treatment strategies and mortality risk prediction in advanced #ovariancancer New global real-world data (n=3,286) finds no difference in 5-year survival between primary surgery & neoadjuvant chemo for advanced ovarian cancer. 💡

We are delighted to share that SUROVA — one of the largest real-world studies ever conducted in ovarian cancer — has just been published in IJGC. 3,500+ patients, 177 centers, 55 countries. M 🔗 authors.elsevier.com/a/1mDLi,NsLd2P…

SUROVA has been selected as “Leader Article of the Month” at IJGC. An extraordinary recognition for a project that unites centers across the world to improve outcomes in advanced ovarian cancer. . 🔗 Article: authors.elsevier.com/a/1mDLi,NsLd2P…

Key SUROVA findings (n=3286): • Overall survival similar between PDS and NACT • Long-term advantage of PDS only when complete resection + no complications • Post-operative complications worsen survival dramatically • Striking ethnic differences ⬇️ 🔗 authors.elsevier.com/a/1mDLi,NsLd2P…

SUROVA shows that real-world outcomes depend not only on treatment choice, but on surgical quality, patient selection, and complication avoidance. This is the future of personalized ovarian cancer care. 🔗 authors.elsevier.com/a/1mDLi,NsLd2P…

Hi SUROVA is open access! Thanks for your patience …l-journal-of-gynecological-cancer.com/article/S1048-… ESGO!!!! IJGC European Network of Young Gynae Oncologists